tirzepatide cvot results cardiovascular outcomes 2024 surpass-cvot Frontiers Tirzepatide cardiovascular event risk assessment:

Controlled human trials exist, but they're limited in size, focused mostly on topical cosmetic use, and usually last only a few weeks or months. That means a lot of the exciting claims, especially around gene expression, systemic repair, and anti-aging effects, haven't been confirmed in large-scale human studies

10.1016/S0303-7207(98)00246-9 32

This isnt a one-size-fits-all treatment

compared GLP-1 agonists to other hypoglycemic agents, including metformin, sulfonylureas, thiazolidinediones, meglitinides, gliptins, and SGLT2 inhibitors

Following your providers recommendations regarding dosage and lifestyle changes can also help maximize the benefits of treatment

Laboratory profile and observed endpoints of Liraglutide and Semaglutide in Kidney [PMID: 39847451] Laboratory literature summary: laboratory profile and observed endpoints of Liraglutide and Semaglutide in Kidney Transplant Recipients